ERBB2 and breast neoplasm: According to the 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines, breast tumors would be considered HER2-positive when IHC 3+ or FISH amplified, whereas HER2-negative is defined as HER2 0, 1+, and 2+ with FISH-negative [6].